medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 6

<< Back Next >>

Ann Hepatol 2013; 12 (6)

Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis

Wei Z, Can L, Bo L, Rong W, Nan Z, Yi-Zhi X, Ying-Ying Y, Feng Z, Hua-Mei Z, Ke-Qiang W, Xiao-Qiu X , Zhang X

Language: English
References: 38
Page: 892-900
PDF size: 212.79 Kb.


ABSTRACT

Objective. Angiotensin II, one component of renin-angiotensin system (RAS), is formed from Ang I by the catalysing of angiotensin converting enzyme (ACE). Angiotensin II plays an important role in the development of insulin resistance. ACE2, a homologue of ACE, couterregulate the actions of angiotensin II by facilitating its breakdown to angiotensin-(1-7). RAS has been implicated in the pathogenesis of non-alcoholic steatohepatitis (NASH). Earlier demonstration that thiazolidinediones (TZDs) improve steatohepatitis promoted us to evaluate the change of hepatic ACE2 expression in rats with high fat diet (HFD)-induced NASH and the effects of TZDs on the hepatic ACE2 expression. Material and methods. Rats were divided into normal control group, high fat diet (HFD) group, and pioglitazone group. After 24 weeks of treatment with pioglitazone, a TZD, we evaluated changes in liver histology, insulin sensitivity, lipid metabolism, circulating RAS levels and hepatic ACE2 expression. Results. Compared with normal controls, the concentrations of serum lipid, aminotransaminase, glucose, insulin, ACE, angiotensin II, ACE2, angiotensin-(1-7) and the degree of hepatic ACE2 expression were significantly higher in rats with HFD-induced NASH. Pioglitazone significantly reduced the concentrations of serum lipid, aminotransaminase, glucose, insulin, ACE, angiotensin II while markedly raised the concentrations of serum ACE2, angiotensin-(1-7) and the degree of hepatic ACE2 expression. Conclusion. Hepatic ACE2 expression markedly increased in rats with HFD-induced NASH and was further upregulated by pioglitazone. Hepatic ACE2 may be a new target of pioglitazone treatment for NASH.


REFERENCES

  1. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009; 50(Suppl.): S412-S416.

  2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.

  3. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-6.

  4. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.

  5. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-72.

  6. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin- angiotensin-aldosterone system. Nat Rev Drug Discov 2002; 1: 621-36.

  7. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43.

  8. Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 2005; 288: F353-F362.

  9. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev 2012; 13: 136-49.

  10. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-9.

  11. Paizis G. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005; 54: 1790-6.

  12. Herath C, Warner F, Lubel J, Dean R, Jia Z, Lew R, Smith A, et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis. J Hepatol 2007; 47: 387-95.

  13. Gupte M, Boustany-Kari CM, Bharadwaj K, Police S, Thatcher S, Gong MC, English VL, et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2008; 295:R781-8.

  14. Toblli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008; 16: 770-6.

  15. McGuire DK, Inzucchi SE. New Drugs for the Treatment of Diabetes Mellitus: Thiazolidinediones and their evolving cardiovascular implications. Circulation 2008; 117: 440-9.

  16. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364-70.

  17. Fan JG, Qiao L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 2009; 8: 233-40.

  18. Lee MY, Lee EY, Lee BJ, Won CS, Koh JH, Shin JY, Shin YG, et al. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei Med J 2007; 48: 301-7.

  19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.

  20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.

  21. Vikram A, Jena G, Ramarao P. Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br J Pharmacol 2010; 161: 1708-21.

  22. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-36.

  23. Scheen A. Glitazones and weight gain. Ann Endocrinol (Paris) 2002; 63: 1S41-1S44.

  24. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 2004; 314: 580-5.

  25. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54: 991-9.

  26. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006; 22: 98-107.

  27. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-9.

  28. Sun Y. The renin-angiotensin-aldosterone system and vascular remodeling. Congest Heart Fail 2002; 8: 11-6.

  29. Sun Y, Weber KT. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med 1998; 30(Suppl. 1): 3-8.

  30. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-62.

  31. Abbas G, Silveira MG, Lindor KD. Hepatic fibrosis and the renin-angiotensin system. Am J Ther 2011; 18: e202-e208.

  32. Herath CB, Lubel JS, Jia Z, Velkoska E, Casley D, Brown L, Tikellis C, et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol 2009; 297: G98-G106.

  33. Yi ET, Liu RX, Wen Y, Yin CH. Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats. Acta Pharmacol Sin 2012; 33: 1518-24.

  34. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-9.

  35. Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, et al. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Hepatol Res 2005; 32: 235-42.

  36. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.

  37. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96.

  38. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Lavine JE, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.




2020     |     www.medigraphic.com